Dr Huaizheng Peng is the General Manager of China Medical System Holdings (CMS), International Investment and Operations. He is responsible for the firm’s international operations and global corporate development, including pharmaceutical assets acquisition, product licencing-in/out, international business development, and asset management. In addition, he is the CEO of CMS Medical Venture, a corporate venture capital fund, and CEO of A&B fund, the investment vehicle of a family office. Both funds are strategically investing in product-orientated companies worldwide.
Dr Peng was formerly a global investor and an investment banker specialising in Life Sciences, biotechnology and pharmaceuticals. He worked as Partner of Northland Bancorp, a private equity firm, Head of Life Sciences and as Director of Corporate Finance at Seymour Pierce, a London-based investment bank and stockbroker, and portfolio manager of global life sciences and Asian Technology at Close Brother Asset Management.
Prior to his financial and pharmaceutical career, he practiced medicine as a clinical lecturer at UCL Medical School, UK, after he received his Bachelor’s and Master’s degrees in Medicine from Hunan Medical College, PR China and his Doctoral of Philosophy from the University of London, UK.